![]() ![]() Mikhail has commercial strategy experience. Mikhail is currently the Head of Commercial for Europe. ![]() This will reverse as the new CEO leads a refreshed leadership team. In the above quant factor grades, Amarin scores a B+ on profitability. By watching the profit and loss results closely, the company may adjust prices lower to increase demand.Īs revenue improves, Amarin’s growth and momentum score will also rise: It will apply its lessons learned in launching in the U.S. OpportunityĪmarin has an opportunity to market and promote the product at an attractive price point in Europe. I would also note that the generic that's in the market and no one that's talking about potentially launching soon, have a label that is limited to, the original label for VASCEPA, which is a triglyceride lowering label for patients with very high triglycerides associated with pancreatitis.Īnd that was about $40 million of our business last year, ain’t to give up $40 million in business, but that's not a growing sector of our business.Īlthough Teva Pharmaceutical ( TEVA) is a threat, the generics giant is unlikely to enter the market aggressively. So, in the short term, generics should not get more than 9% of the market share initially. Conversely, Amarin’s suppliers have dedicated manufacturing facilities. So far, Amarin is not aware of any generic companies investing heavily in the capital. With three generics on the market, the company that operates at the lowest cost has an advantage. Investors are concerned about generic competition disrupting sales of VASCEPA. Furthermore, market access and launching the product in Germany will drive sales higher.īy the end of the year, Amarin anticipates China will approve VASCEPA, further increasing its global addressable market. In Europe, approval of VAZKEPA in March-April suggests that revenue will expand. Plus, managed care coverage for the brand is getting better. It needs to build its brand to differentiate. Amarin said ( on slide 6) at the Jefferies Healthcare Conference that it can grow faster than generics. Despite its growing headwinds, generic competition is currently limited. ![]() Poor market awareness limited the product’s sales. Last year, prescription growth led to $610 million in VASCEPA revenue. Source: Jefferies healthcare conference presentation ![]() Instead, investors will turn their attention to how much market share it will get in the cardiovascular market.Ĭardiovascular Disease (“CVD”) is a health burden. Amarin claimed, at the time, the denial was an “over-invalidation of patents through hindsight bias and the suppression of innovation.” Had the court ruled in the company’s favor, AMRN stock would have broken out to new highs. Markets already expected and priced in the Supreme Court rejecting its petition to revive VASCEPA patents. How much longer must investors wait before the stock turns higher from here? VASCEPA Patent Rejection Investors who did not sell the stock are now at break-even since my last write-up. Did markets anticipate at the time that months later, the Supreme Court would reject its bid to revive VASCEPA patents ? AMRN stock fell despite posting strong quarterly results. When Amarin ( NASDAQ: AMRN) traded above the $8.00 fair value ( posted here) earlier this year, the rally did not last. ![]()
0 Comments
Leave a Reply. |